TINI 2: Total Therapy for Infants with Acute Lymphoblastic Leukemia II

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Blinatumomab (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Mercaptopurine (Primary) ; Mercaptopurine (Primary) ; Methotrexate (Primary) ; Methotrexate (Primary) ; Methotrexate (Primary) ; Mitoxantrone (Primary) ; Pegaspargase (Primary) ; Vorinostat (Primary) ; Vorinostat (Primary) ; Ziftomenib (Primary)
Indications Acute biphenotypic leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use
Acronyms TINI 2

10 Dec 2024 Results (n=27) presented at the 66th American Society of Hematology Annual Meeting and Exposition
02 Jan 2024 Status changed from not yet recruiting to recruiting.
11 Sep 2023 Planned initiation date changed from 1 Jul 2023 to 1 Nov 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com